Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 2/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14915231 | 1.00 | BTK (0.44) | BTKCLK2VNN1GRM5KDM4E | |
| SCHEMBL14914546 | 1.00 | BTK (0.44) | BTKCLK2VNN1GRM5KDM4E | |
| SCHEMBL29742163 | 0.88 | BTK (0.45) | BTKCLK2VNN1GRM5KDM4E | |
| SCHEMBL14914719 | 0.88 | BTK (0.45) | BTKCLK2VNN1GRM5KDM4E | |
| SCHEMBL14914844 | 0.88 | BTK (0.45) | BTKCLK2VNN1GRM5KDM4E | |
| SCHEMBL14914721 | 0.88 | BTK (0.45) | BTKCLK2VNN1GRM5KDM4E | |
| SCHEMBL31158065 | 0.88 | BTK (0.45) | BTKCLK2VNN1GRM5KDM4E | |
| SCHEMBL17998822 | 0.81 | VNN1 (0.44) | BTKCLK2VNN1GRM5KDM4E | |
| SCHEMBL14926077 | 0.81 | GRM5 (0.46) | BTKCLK2VNN1GRM5KDM4E | |
| SCHEMBL14926064 | 0.81 | GRM5 (0.46) | BTKCLK2VNN1GRM5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773632-B1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| EP-2773632-B1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| EP-2773632-A1 | 8-FLUOROPHTHALAZIN-1 (2H) - ONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-8754077-B2 | 8-fluorophthalazin-1(2H)-one compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-8754077-B2 | 8-fluorophthalazin-1(2H)-one compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-8754077-B2 | 8-fluorophthalazin-1(2H)-one compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20140128401-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128401-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128401-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8669251-B2 | 8-fluorophthalazin-1(2H)-one compounds | GENENTECH, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669251-B2 | 8-fluorophthalazin-1(2H)-one compounds | GENENTECH, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669251-B2 | 8-fluorophthalazin-1(2H)-one compounds | GENENTECH, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| WO-2013067264-A1 | 8-FLUOROPHTHALAZIN-1 (2H) - ONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067264-A1 | 8-FLUOROPHTHALAZIN-1 (2H) - ONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116246-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116246-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116246-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116246-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | BTK, LCK, SYK | BTK 1/4885CLK2 188/4885VNN1 3589/4885 |
| US-20140128401-A1 | 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS | BTK, LCK, SYK | BTK 1/4885CLK2 263/4885VNN1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.